Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients
NCT02073981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1021
Last updated 2023-08-07
Summary
This study is implemented to identify factors having an impact on improvement or exacerbation of non-motor symptoms, to provide information contributing to development of medical care in this field and improvement of patients' QOL, and to clarify the association between the use of istradefylline and non-motor symptoms or QOL.
Conditions
- Parkinson Disease
Sponsors & Collaborators
-
Kyowa Kirin Co., Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2016-05-31
- Completion
- 2023-06-30
Countries
- Japan
More Related Trials
-
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
NCT00455507 ·Status: COMPLETED ·Phase: PHASE2
-
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628 ·Status: COMPLETED ·Phase: PHASE1
-
Idebenone Treatment of Early Parkinson's Diseasesymptoms
NCT03727295 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
NCT05931575 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
NCT03703570 ·Status: COMPLETED ·Phase: PHASE2
-
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
NCT00456794 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MK0657 in Parkinson's Disease Patients (0657-006)
NCT00505843 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01173731 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01491529 ·Status: COMPLETED ·Phase: PHASE2
-
Survey on PD Patients With Depressive Symptoms
NCT00614575 ·Status: COMPLETED
-
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
NCT00955526 ·Status: COMPLETED ·Phase: PHASE3
-
Istradefylline Effect Protocol on Parkinson's Disease Tremor
NCT05885360 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01385592 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
NCT01294800 ·Status: COMPLETED ·Phase: PHASE2
-
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
NCT00957918 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
NCT00456586 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
NCT00955045 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease
NCT02066571 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
NCT04056689 ·Status: COMPLETED ·Phase: PHASE1
-
Istradefylline for Parkinson Disease With Cognitive Impairment
NCT05333549 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
NCT06175767 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
NCT05709301 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
NCT00727727 ·Status: COMPLETED
-
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
NCT03845387 ·Status: COMPLETED ·Phase: PHASE2